Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 55 | 2023 | 109 | 10.800 |
Why?
|
| Graft vs Host Disease | 23 | 2023 | 50 | 4.270 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 49 | 2.900 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 28 | 1.680 |
Why?
|
| Transplantation Conditioning | 23 | 2023 | 39 | 1.430 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 31 | 0.950 |
Why?
|
| Transplantation, Homologous | 17 | 2023 | 249 | 0.930 |
Why?
|
| Humans | 67 | 2023 | 25178 | 0.830 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 17 | 0.830 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 11 | 0.770 |
Why?
|
| Hodgkin Disease | 4 | 2021 | 16 | 0.720 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 33 | 0.700 |
Why?
|
| Recurrence | 13 | 2023 | 291 | 0.660 |
Why?
|
| Eye Diseases | 4 | 2019 | 7 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 209 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 182 | 0.630 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 4 | 0.620 |
Why?
|
| Retrospective Studies | 24 | 2023 | 3105 | 0.620 |
Why?
|
| Middle Aged | 27 | 2023 | 8135 | 0.540 |
Why?
|
| Adult | 27 | 2023 | 7087 | 0.540 |
Why?
|
| Cyclophosphamide | 8 | 2023 | 44 | 0.530 |
Why?
|
| Salvage Therapy | 3 | 2021 | 34 | 0.510 |
Why?
|
| Transplantation, Autologous | 8 | 2022 | 144 | 0.450 |
Why?
|
| Prognosis | 12 | 2023 | 726 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 61 | 0.410 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 152 | 0.410 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 20 | 0.400 |
Why?
|
| Calcineurin Inhibitors | 5 | 2023 | 15 | 0.380 |
Why?
|
| Adolescent | 12 | 2023 | 1998 | 0.380 |
Why?
|
| Male | 23 | 2022 | 13545 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 14 | 0.360 |
Why?
|
| Aged | 20 | 2023 | 8397 | 0.360 |
Why?
|
| Young Adult | 12 | 2021 | 1749 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 8 | 0.340 |
Why?
|
| Allografts | 5 | 2021 | 187 | 0.310 |
Why?
|
| Female | 22 | 2023 | 13844 | 0.310 |
Why?
|
| Survival Rate | 8 | 2021 | 310 | 0.290 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.270 |
Why?
|
| Splenic Diseases | 1 | 2006 | 3 | 0.270 |
Why?
|
| Rituximab | 3 | 2023 | 45 | 0.260 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 13 | 0.260 |
Why?
|
| Melphalan | 5 | 2023 | 12 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 119 | 0.230 |
Why?
|
| Risk Factors | 5 | 2023 | 2166 | 0.220 |
Why?
|
| Mycoses | 1 | 2023 | 20 | 0.220 |
Why?
|
| Quality of Life | 4 | 2022 | 594 | 0.220 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.220 |
Why?
|
| Bacterial Infections | 1 | 2023 | 50 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 2 | 0.210 |
Why?
|
| POEMS Syndrome | 1 | 2022 | 1 | 0.210 |
Why?
|
| Remission Induction | 5 | 2022 | 86 | 0.200 |
Why?
|
| Unrelated Donors | 4 | 2023 | 5 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2019 | 41 | 0.200 |
Why?
|
| Vidarabine | 4 | 2023 | 9 | 0.200 |
Why?
|
| Autografts | 2 | 2019 | 29 | 0.200 |
Why?
|
| Bone Marrow | 4 | 2023 | 73 | 0.200 |
Why?
|
| Hypogonadism | 1 | 2021 | 7 | 0.200 |
Why?
|
| Infertility | 1 | 2021 | 8 | 0.200 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 18 | 0.190 |
Why?
|
| Busulfan | 4 | 2023 | 4 | 0.190 |
Why?
|
| Heart Failure | 1 | 2023 | 180 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 22 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 12 | 0.190 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 4 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 6 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 14 | 0.190 |
Why?
|
| Siblings | 4 | 2022 | 17 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 35 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 39 | 0.180 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 9 | 0.180 |
Why?
|
| Return to Work | 1 | 2021 | 49 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 9 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 4 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 3 | 0.180 |
Why?
|
| Infliximab | 1 | 2020 | 16 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 327 | 0.170 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2021 | 233 | 0.170 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.170 |
Why?
|
| Steroids | 1 | 2019 | 23 | 0.170 |
Why?
|
| Neoplasms | 1 | 2022 | 213 | 0.170 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.170 |
Why?
|
| Mucositis | 1 | 2019 | 4 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 174 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 4 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2019 | 40 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 84 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 30 | 0.160 |
Why?
|
| Incidence | 4 | 2023 | 664 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 233 | 0.150 |
Why?
|
| Acute Disease | 3 | 2023 | 185 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 37 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 11 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2023 | 588 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 498 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2023 | 407 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3146 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1621 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4503 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2012 | 24 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 37 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 592 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 50 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 62 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2022 | 1756 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 175 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 19 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 16 | 0.090 |
Why?
|
| Prednisone | 2 | 2023 | 59 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2023 | 51 | 0.090 |
Why?
|
| Mutation | 2 | 2023 | 306 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2020 | 61 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 154 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 136 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 11 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 24 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1589 | 0.080 |
Why?
|
| Registries | 2 | 2020 | 161 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 278 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 450 | 0.080 |
Why?
|
| Pain | 2 | 2021 | 365 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 315 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1232 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 649 | 0.070 |
Why?
|
| United States | 2 | 2023 | 1899 | 0.070 |
Why?
|
| Splenomegaly | 1 | 2006 | 3 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 5 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2006 | 8 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2006 | 48 | 0.070 |
Why?
|
| Fever | 1 | 2006 | 34 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 294 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 19 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.060 |
Why?
|
| Voriconazole | 1 | 2023 | 11 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 34 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 68 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 10 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 12 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 3 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 7 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 50 | 0.050 |
Why?
|
| Canada | 1 | 2020 | 47 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 67 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 55 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 50 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 39 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 45 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 51 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 45 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 10 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 3 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 69 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 5 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 66 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 720 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 144 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 14 | 0.040 |
Why?
|
| Mass Screening | 1 | 2018 | 161 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2017 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 18 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 29 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2017 | 32 | 0.040 |
Why?
|
| Methotrexate | 1 | 2017 | 36 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2018 | 126 | 0.040 |
Why?
|
| Inflammation | 1 | 2018 | 253 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 537 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 111 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 307 | 0.020 |
Why?
|